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Abstract
In many applications, an ability of liposomes to retain drug and then rapidly release it at some later time would be of benefit. In this work,
we investigate the ability of cationic large unilamellar vesicles (LUV) to promote rapid release of doxorubicin from anionic LUV. It is shown
that the addition of cationic liposomes containing cholesterol, dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylcholine
(DSPC) and the cationic lipid N,N-dioleyl-N,N-dimethylammonium chloride (DODAC) to doxorubicin-containing LUV composed of
cholesterol, DOPE, DSPC and the anionic lipid dioleoyphosphatidylglycerol (DOPG) can result in release of more than 90% of the drug in
times of 30 s or less. Further, it is shown that these release characteristics are exquisitely dependent on the presence of DOPE and cholesterol.
In the absence of DOPE, much slower release rates are observed, with maximum release levels of 50% after a 2-h incubation at 20 jC.
Remarkably, threshold levels of more than 10 mol% cholesterol are required before any appreciable release is observed. [31P]NMR
spectroscopy and freeze-fracture electron microscopy studies reveal that systems giving rise to rapid release of doxorubicin exhibit limited
formation of inverted hexagonal (HII) phase, suggesting that these lipids facilitate drug release by formation of local regions of non-bilayer
structure. It is concluded that drug release triggered by mixing anionic and cationic liposomes could be of utility in drug delivery
applications.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes that exhibit regulated release properties have
considerable potential for drug delivery. Interest in this area
has resulted in construction of liposomes that are sensitive
to temperature, light, pH and other stimuli [1]. In most
cases, sensitization of liposomes was achieved by modifi-
cation of the liposomal surface with pH-sensitive or ther-
mosensitive polymers [2,3] or by inclusion of ionizable
lipids in the liposomal bilayer [3–7].
In previous works, we and others [8–14] have noted
that addition of cationic LUV to anionic LUV results in
disruption of the LUV structure as evidenced by the
formation of larger structures, lipid mixing phenomena
[10,12,13] and, in some cases, formation of non-bilayer
structures [7,14]. These studies suggest that if the anionic
or cationic LUV contained encapsulated drug, considerable
drug release would be expected on addition of the oppo-
sitely charged LUV population. In the present work, we test
this hypothesis, paying particular attention to the influence
of dioleoylphosphatidylethanolamine (DOPE) and choles-
terol, two lipids that have been shown to favour or facilitate
formation of non-bilayer structures such as the inverted
hexagonal (HII) phase [15,16]. Employing anionic doxor-
ubicin-containing LUV, we show that rapid release of
encapsulated doxorubicin can be achieved on addition of
cationic LUV and that this rapid release correlates with
formation of non-bilayer lipid structures demonstrated by
[31P]NMR and freeze-fracture techniques. Further, we show
that the presence of both DOPE and cholesterol is essential
for rapid release to be observed. These results are discussed
in terms of the potential utility of these systems for
triggered release applications.
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2. Materials and methods
2.1. Materials
N,N-dimethyl-N,N-di-9-cis-octadecenylammonium
chloride (DODAC) was provided by Dr. J. Gaucheron,
University of British Columbia (Vancouver, BC, Canada).
1,2-Dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were
obtained from Avanti Polar Lipids (Alabaster, AL). Choles-
terol (Chol) and doxorubicin hydrochloride were purchased
from Sigma Chemical Company (St. Louis, MO). 1-O-(2V-
(N-methoxypolyethylene-glycol)succinoyl)-2-N-myristoyl-
sphyngosine (PEG-CerC14) was obtained from Inex Phar-
maceuticals (Burnaby, BC, Canada). All other reagents used
in this study were of analytical grade.
2.2. Vesicle preparation
Aqueous dispersions of lipids were obtained by hydrat-
ing a lipid film, which was prepared by co-dissolving lipids
to desired molar ratios and drying under a nitrogen stream
followed by the removal of residual solvent under high
vacuum. Dried lipid films were hydrated with 300 mM
aqueous solution of ammonium sulfate or 150 mM saline
with five freeze–thaw cycles (liquid N2/60 jC) to give
multilamellar vesicle (MLV) suspensions. Large unilamellar
vesicles (LUV) were generated by extrusion of MLVs
through two stacked Nuclepore polycarbonate filters with
a pore size of 100 nm (10 passes) using an extrusion device
obtained from Lipex Biomembranes (Vancouver, BC, Can-
ada). The mean diameter of LUVs was determined by
dynamic light scattering using a NICOMP 370 particle sizer
(Nicomp Particle Sizing Inc., Santa Barbara, CA) and found
117F 25 nm. Phospholipid concentrations were determined
by established methods [17].
2.3. Doxorubicin loading and leakage assay
LUVs dispersed in ammonium sulfate solution were
used for loading with doxorubicin [18]. An ammonium
sulfate gradient was generated by exchanging the extra-
vesicular solution with 150 mM NaCl, pH 7.4 on Sephadex
G-50 spin columns [19]. Doxorubicin hydrochloride was
then added to the LUVs (5 mM total lipid) to give a molar
drug-to-lipid ratio of 0.05. The samples were incubated at
60 jC for 1 h to provide optimal loading conditions.
Unentrapped doxorubicin was removed by running the
samples over Sephadex G-50 spin columns prior to detec-
tion of liposomally entrapped drug.
To estimate the percentage of doxorubicin leakage from
liposomes, an aliquot of liposomal doxorubicin was dil-
uted 500-fold by injection into a cuvette containing 150
mM saline and the fluorescence intensity of doxorubicin
was measured (excitation and emission wavelengths 480
and 590 nm, respectively) with a Perkin-Elmer LS50 fluo-
rimeter (Perkin-Elmer, Norwalk, CT). The value for 100%
leakage was obtained by addition of 10% Triton X-100 to
a final concentration of 0.5%. The percentage of leakage
of doxorubicin at a given time was calculated according
to:
%leakage ¼ ðF  F0Þ=ðF100  F0Þ  100
where F is the fluorescence intensity of the sample at a
given time, and F0 and F100 are intensities of samples
before inducing leakage and after addition of Triton X-
100, respectively.
2.4. Freeze-fracture electron microscopy
Samples were cryofixed in the presence of 33% glycerol
by plunging them into liquid Freon 22 cooled by liquid
nitrogen. The fractured surface was shadowed unidirection-
ally with platinum (45j) and coated with carbon (90j)
employing a Balzers freeze-etching system BAF 400D
(Balzers, Liechtenstein). Replicas were analysed using a
JEOL model JEM 1200EX electron microscope (Soquelec,
Montreal, Canada).
2.5. [31P]NMR spectroscopy
Proton decoupled [31P]NMR spectra were obtained using
a Bruker MSL-200 spectrometer operating at 81.02 MHz.
Acquisition parameters included 3.0-As 60j pulse, a spectral
width of 25 kHz with 4 k data points and a 1-s interpulse
delay time. The sample temperature (F 1 jC) was regulated
using a Bruker VT-100 temperature controller. If not other-
wise indicated, the temperature was maintained at 25 jC.
An exponential multiplication corresponding to 50 Hz line
broadening was applied to the free induction decays prior to
Fourier transformation. The chemical shift was referenced to
external 85% phosphoric acid (H3PO4).
3. Results
3.1. Characterization of charged liposomal systems
LUVs composed of DSPC, DOPE, cholesterol and
charged lipids (anionic, DOPG or cationic, DODAC) at
varying ratios were used throughout these studies. Both
DOPG and DODAC are permanently charged and are lipids
that preferentially adopt the bilayer phase upon hydration.
The presence of DOPE (which facilitates the formation of
the HII phase) at levels up to 17 mol% did not destabilize the
lipid bilayer of charged LUVs at room temperature. Main-
taining the phospholipids/cholesterol (1:1) ratio while add-
ing increased levels of DOPE was achieved by appropriate
adjustment of DSPC levels. To evaluate the effect of a
poly(ethylene)glycol (PEG) coating on the interaction of
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oppositely charged vesicles, PEG-CerC14 was included in
some liposomal preparations.
Doxorubicin was loaded into anionic and cationic
LUVs (DSPC/DOPE/charged lipid/Chol at varying mole
ratios) in response to a pH gradient induced by ammo-
nium sulfate. We found that this method could be used for
loading doxorubicin into both cationic and anionic lip-
osomes; however, the anionic liposomes were slightly
more stable and thus doxorubicin was loaded into the ani-
onic LUV in all the experiments conducted here. Effi-
ciency of encapsulation with initial doxorubicin-to-lipid
ratio = 0.05 was close to 100%. No leakage of entrapped
doxorubicin from anionic LUVs was detected over a 1-h
incubation time.
3.2. Effect of charged lipid content on doxorubicin release
Initial studies were conducted to determine whether
release of encapsulated doxorubicin upon mixing of charged
LUVs that did not contain DOPE could be achieved by
increasing the charged lipid content in liposome prepara-
tions. Mixing of equal volumes of doxorubicin-containing
DSPC/DOPG/Chol (34:17:50) LUV and DSPC/DODAC/
Chol (34:17:50) LUV (4 mM total lipid in both populations)
resulted in rapid aggregation that appeared as a transforma-
tion of the translucent LUV preparations to turbid, milky
dispersions. Quasi-elastic light scattering measurements
revealed formation of large structures with a broad size
distribution (400–600 nm). As shown in Fig. 1, these
systems show some leakage of doxorubicin upon mixing
where the initial rate increased with the charged lipid
content. However, the leakage did not exceed 50% of the
total encapsulated doxorubicin after a 2-h incubation at 20
jC even at 40 mol% charged lipid content.
3.3. Effect of DOPE and cholesterol on triggered release
properties of LUVs
Both DOPE and cholesterol promote the formation of
non-bilayer structures such as the HII phase in mixed
lipid systems [14–16,20–22]. If the mechanism of
release involves formation of HII phase or related non-
bilayer structures, it would be expected that inclusion of
DOPE and/or cholesterol into the bilayer of the cationic
and anionic liposomes should promote more extensive
bilayer destabilization upon interaction, resulting in faster
release.
Fig. 2 shows time courses of doxorubicin leakage from
DSPC/DOPE/DOPG/Chol liposomes induced by mixing
with DSPC/DOPE/DODAC/Chol liposomes at varying
DOPE content. Comparing these data to those shown in
Fig. 1, it is apparent that the presence of DOPE remark-
ably enhances both the rate and the amount of doxor-
ubicin leakage. At 17 mol% DOPE, release of 90% of the
encapsulated doxorubicin was observed within 30 s after
mixing. It may be noted that the interactions of the
DOPE-containing LUVs giving rise to maximum doxor-
ubicin leakage gave rise to aggregation that produced
particles larger than could be measured by light scatter-
ing.
The effect of cholesterol on the leakage of doxorubicin
from anionic DSPC/DOPE/DOPG/Chol LUVs following
mixing with cationic DSPC/DOPE/DODAC/Chol LUVs is
illustrated in Fig. 3. Remarkably, as the cholesterol content
was increased from 10 to 17 mol%, the doxorubicin leakage
increased from less than 5% over 2 h to more than 90%
within 30 s. It may be concluded that cholesterol is
absolutely required to achieve the rapid release rates suitable
for ‘‘triggered release’’ applications.
Fig. 1. Release of doxorubicin from anionic LUVs after mixing with equi-
molar amounts of cationic LUVs. Lipid compositions: (n) DSPC/charged
lipid/Chol (34:17:50), (.) DSPC/charged lipid/Chol (25:25:50), (E)
DSPC/charged lipid/Chol (30:30:40), (z) DSPC/charged lipid/Chol
(20:40:40). DOPG and DODAC were used as charged components for
anionic and cationic LUVs, respectively. The arrow indicates the moment
of mixing.
Fig. 2. Effect of DOPE on the rate of doxorubicin release from anionic
LUVs after mixing with equimolar amounts of cationic LUVs. Lipid
compositions: (n) DSPC/charged lipid/Chol (34:17:50), (.) DSPC/DOPE/
charged lipid/Chol (29:4:17:50), (E) DSPC/DOPE/charged lipid/Chol
(25:8:17:50), (z) DSPC/DOPE/charged lipid/Chol (17:17:17:50). DOPG
and DODAC were used as charged components for anionic and cationic
LUVs, respectively. The arrow indicates the moment of mixing.
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3.4. Structural properties of the lipid dispersions produced
on mixing cationic and anionic LUV
It is well established [23] that phospholipids organized in
(large) bilayer structures give rise to [31P]NMR spectra with
a characteristic asymmetric line shape with a high field peak
and a low field shoulder, displaying a residual chemical shift
anisotropy of approximately  40 ppm for lipids in the
liquid crystalline state. In contrast, phospholipids such as
DOPE that adopt the inverted hexagonal phase in isolation
exhibit reversed asymmetry compared to the ‘‘bilayer’’ line
shape with a chemical shift anisotropy that is a factor of two
smaller than observed for bilayer spectra.
As shown in Fig. 4A–B, the lipid dispersion produced on
mixing equimolar amounts of DSPC/DOPG/Chol (34:17:50)
and DSPC/DODAC/Chol (34:17:50) LUV reveals the
[31P]NMR line shape associated with bilayer structure.
Incorporation of DOPE (in the absence of cholesterol) also
resulted in a bilayer line shape (Fig. 4C,D). However, a
mixture of DSPC/DOPE/DOPG/Chol (17:17:17:50) and
DSPC/DOPE/DODAC/Chol (17:17:17:50) LUVs gave rise
to a spectrum in which a weak HII phase signal was super-
imposed on a bilayer signal (Fig. 4E), suggesting that part of
lipid molecules adopted the HII phase upon mixing. When
doxorubicin was present in the anionic LUVs, a significant
increase in the size of the HII component was observed (Fig.
4F). In order to unambiguously establish that the super-
imposed [31P]NMR resonance corresponded to HII phase
lipid and not a narrow ‘‘isotropic’’ peak arising from small
vesicles, the chemical shift of the superimposed peak was
compared to that arising from inorganic phosphate (see Fig.
4G). The chemical shift difference of 6.8 ppm is consistent
with the superimposed peak arising from HII structure. In
summary, these data show that, in systems that exhibit rapid
release, the lipid dispersions obtained on mixing the anionic
and cationic LUV exhibit limited HII phase structure. In
addition, these results suggest that doxorubicin itself exerts
an additional disordering effect on the lipid bilayer structure,
inducing formation of larger HII phase domains and therefore
promoting its own release.
The structures of the dispersions formed on mixing of
oppositely charged LUVs were also examined by freeze-
fracture electron microscopy. It was found that mixed
anionic DSPC/DOPE/DOPG/Chol (17:17:17:50) LUV (that
did not contain doxorubicin) and cationic DSPC/DOPE/
DODAC/Chol (17:17:17:50) LUVs predominantly form
aggregates (Fig. 5B). However, mixing of anionic doxor-
ubicin-loaded LUVs with cationic vesicles resulted in for-
mation of significantly bigger aggregates and some very
large particles (Fig. 5C). Fragments of some structures
reveal the characteristic striated pattern attributed to lipids
Fig. 4. [31P]NMR spectra obtained from dispersions resulting from mixing
of cationic and anionic LUVs. The LUVs were composed of: (A) DSPC/
charged lipid/Chol (34:17:50), (B) DSPC/charged lipid/Chol (34:17:50)
with doxorubicin loaded into anionic LUVs, (C) DSPC/DOPE/charged
lipid (66:17:17), (D) DSPC/DOPE/charged lipid (66:17:17) with doxor-
ubicin loaded into the anionic LUVs, (E) DSPC/DOPE/charged lipid/Chol
(17:17:17:50), (F) DSPC/DOPE/charged lipid/Chol (17:17:17:50) with
doxorubicin loaded into the anionic LUVs, (G) DSPC/DOPE/charged lipid/
Chol (17:17:17:50) with doxorubicin loaded into anionic LUVs and
inorganic phosphate present in the extraliposomal media. DOPG and
DODAC were used as charged components for the anionic and cationic
LUVs, respectively.
Fig. 3. Effect of cholesterol on the rate of doxorubicin release from anionic
LUVs after mixing with equimolar amounts of cationic LUVs. Lipid
compositions: (n) DSPC/DOPE/charged lipid (66:17:17), (.) DSPC/
DOPE/charged lipid/Chol (56:17:17:10), (D) DSPC/DOPE/charged lipid/
Chol (50:17:17:17), (z) DSPC/DOPE/charged lipid/Chol (17:17:17:50).
DOPG and DODAC were used as charged components for anionic and
cationic LUVs, respectively. The arrow indicates the moment of mixing.
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organized in the hexagonal HII phase (Fig. 5D). In agree-
ment with the results obtained by [31P]NMR, these data
support the presence of non-bilayer HII phase structure in
the lipid dispersions resulting from mixing cationic and
anionic LUV that give rise to rapid release of encapsulated
doxorubicin.
3.5. Incorporation of PEG-CerC14 prevents doxorubicin
release
Previous studies have shown that a PEG coating can
inhibit calcium-induced fusion between LUVs [12]. It was
therefore of interest to determine whether incorporation of a
PEG-lipid could prevent release of contents upon mixing of
oppositely charged LUVs. It was found that inclusion of 7.5
mol% of PEG-CerC14 into both the cationic and anionic
vesicles prevents virtually any leakage of encapsulated
doxorubicin following mixing (Fig. 6). However, when the
PEG-CerC14 content was decreased to 5 mol%, release of
about 22% of liposomal doxorubicin occurred within 30 s
after mixing. Interestingly, during the next 15 min of
incubation, quenching of doxorubicin fluorescence was
observed. This effect cannot be attributed to the self-associ-
ation of doxorubicin because of the low doxorubicin con-
centration in the extraliposomal media. Rather, it suggests
that a considerable fraction of PEG-coated doxorubicin-
containing LUVs maintains a transmembrane pH gradient
sufficient to reload doxorubicin released from destabilized
vesicles. Dynamic light scattering did not reveal an increase
of particle size after mixing of LUVs containing 7.5% or 5%
PEG. When the PEG content was diminished to 2.5 mol%, a
similar ‘‘reloading’’ effect was observed, but, in this case,
released doxorubicin was not completely reencapsulated and
the liposome size and polydispersity increased from
117F 30 to 155F 36 nm. It should be noted that inhibition
of doxorubicin release upon mixing was also achieved when
10 mol% PEG-CerC14 was present only in the doxorubicin-
loaded LUVs (data not shown).
Fig. 5. Freeze-fracture electron micrographs of liposome preparations. (A) DSPC/DOPE/DOPG/Chol (17:17:17:50) LUV formed by extrusion through two
stacked filters with 0.1 Am pore size, (B) equimolar mixture of oppositely charged DSPC/DOPE/charged lipid/Chol (17:17:17:50) LUVs, (C) equimolar
mixture of oppositely charged DSPC/DOPE/charged lipid/Chol (17:17:17:50) LUVs with doxorubicin loaded into the anionic LUVs, (D) formation of HII
phase structures in mixtures of DSPC/DOPE/charged lipid/Chol (17:17:17:50) LUVs in the presence of doxorubicin. Original magnification was 20000 , and
the bar represents 200 nm.
Fig. 6. Effect of PEG-CerC14 coating on the rate of doxorubicin release
from the anionic LUVs after mixing with equimolar amounts of cationic
LUVs. Lipid compositions: (n) DSPC/DOPE/charged lipid/Chol/PEG-
CerC14 (17:17:17:50:7.5), (o) DSPC/DOPE/charged lipid/Chol/PEG-
CerC14 (17:17:17:50:5), (E) DSPC/DOPE/charged lipid/Chol/PEG-CerC14
(17:17:17:50:2.5). DOPG and DODAC were used as the charged
components for anionic and cationic LUVs, respectively. The arrow
indicates the moment of mixing.
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4. Discussion
The results of this study demonstrate that relatively
immediate and complete release of doxorubicin encapsu-
lated in anionic LUV can be achieved on mixing with
cationic LUV and that this release is dependent on the
presence of DOPE and cholesterol. Three interesting aspects
of this work concern the mechanism of drug release, the role
of lipids such as DOPE and cholesterol and the potential
applications of these systems for triggered release of drug in
vivo. We discuss these areas in turn.
The mechanism whereby the addition of cationic LUV
to doxorubicin-containing anionic LUV induces drug
release is clearly not just due to aggregation. It may be
noted that for all the systems investigated here, consider-
able aggregation as evidenced by an increased particle size
as determined by QELS occurred on addition of the
cationic LUV to the anionic, drug-containing LUV. How-
ever, in the absence of DOPE and/or cholesterol little or no
release of drug is observed, indicating that aggregation
alone does not result in particularly rapid or complete
release. Equally, however, the release cannot be correlated
with fusion. The [31P]NMR spectra resulting from the
dispersions of cationic and anionic LUV prepared in the
absence of DOPE or cholesterol are classical ‘‘bilayer’’
spectra consistent with lipid structures of 200 nm diameter
or larger [24], much larger than the 100 nm LUV that these
structures originated from. These structures must be fused,
rather than stacked, as stacked 100 nm diameter systems
would be expected to give rise to considerable narrower
spectra due to motional averaging effects arising from
lateral diffusion processes [24]. The parameter that appears
to correlate most closely with the ability of cationic LUV to
cause rapid and complete release of doxorubicin entrapped
in anionic LUV is the appearance of an HII phase compo-
nent in the resulting lipid dispersion. That the presence of a
local region of HII structure should give to rapid leakage is
perhaps not unexpected, given that it represents a relatively
massive and potentially long-lived perturbation of local
bilayer structure.
The requirement for DOPE and cholesterol in order to
achieve rapid release of doxorubicin can be readily under-
stood in terms of a need for local regions of non-bilayer
structure. DOPE assumes the HII phase in isolation and
progressively promotes non-bilayer organization when
incorporated in bilayer systems [16]. Similarly, cholesterol
has long been noted to induce HII structure in mixed
DOPE–DOPC systems [21]. Assuming complete mixing
of lipids following addition of the cationic DSPC/DOPE/
DODAC/Chol (17:17:17:50) LUV to the anionic DSPC/
DOPE/DOPG/Chol (17:17:17:50) LUV, the lipid composi-
tion of the dispersions produced is DSPC/DOPE/DODAC/
DOPG/cholesterol (1:1:0.5:0.5:3). Given that mixtures of
DODAC and DOPG assume the HII phase organization
[14], the ratios of bilayer lipid, HII phase-preferring lipid
and cholesterol are then 1:2:3. Previous studies have dem-
onstrated appreciable formation of HII phase structure in
mixed lipid systems where the ratio of bilayer lipid, HII
phase lipid and cholesterol are 1:2:1 [21].
There are several ways in which triggered release of
encapsulated drug arising from mixing cationic and anionic
LUV could be of utility for in vivo drug delivery applica-
tions, all of which involve the use of PEG-coated LUV
systems. Briefly, the results presented here demonstrate that
the interactions between the LUV and subsequent release of
drug can be inhibited by the presence of a PEG coating. In
previous work [25], we have demonstrated that the dissoci-
ation rates of PEG-ceramides can be modulated by varying
the length of the acyl chain associated with the ceramide
anchor. For example, the dissociation rates increase from
< 1 min for PEG-CerC8 to 1.2 h for PEG-CerC14 and to
more than 13 days for PEG-CerC20. Two circumstances
leading to time-dependent triggered release can be envis-
aged. The first involves co-administering PEG-coated pop-
ulations of cationic and anionic LUV, one or both of which
contains the drug, and relying on the dissociation of the
PEG-lipid to render the systems vulnerable to interaction
and drug release. Alternatively, the drug could be encapsu-
lated in PEG-coated cationic LUVand drug release triggered
by interaction with the negatively charged constituents
associated with the membranes of cells in vivo, following
dissociation of the PEG coating. This would require that
rapid release can occur when only one of the membranes
contains phosphatidylethanolamine on the outer monolayer,
a circumstance that is not characterized here. These and
other possibilities are currently being investigated.
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